John C.M. Farquhar Sells 22,562 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) CEO John C.M. Farquhar sold 22,562 shares of the stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total value of $619,552.52. Following the sale, the chief executive officer directly owned 591,656 shares in the company, valued at $16,246,873.76. This trade represents a 3.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Heartflow Stock Performance

Shares of HTFL opened at $26.95 on Thursday. Heartflow, Inc. has a twelve month low of $25.36 and a twelve month high of $41.22. The company has a market capitalization of $2.30 billion and a PE ratio of -14.89. The firm’s 50-day moving average is $30.24.

Analyst Ratings Changes

HTFL has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Stifel Nicolaus raised their price target on Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Wells Fargo & Company assumed coverage on Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price target for the company. Canaccord Genuity Group upped their price objective on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, JPMorgan Chase & Co. raised their target price on shares of Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Heartflow has an average rating of “Moderate Buy” and a consensus price target of $38.50.

Institutional Investors Weigh In On Heartflow

A number of institutional investors have recently made changes to their positions in HTFL. TFC Financial Management Inc. bought a new position in shares of Heartflow during the 3rd quarter valued at $40,000. Legal & General Group Plc purchased a new position in shares of Heartflow in the third quarter worth about $59,000. Strs Ohio bought a new stake in shares of Heartflow in the 4th quarter valued at about $99,000. Staley Capital Advisers Inc. purchased a new stake in Heartflow during the 4th quarter valued at about $204,000. Finally, Connable Office Inc. bought a new position in Heartflow during the 4th quarter worth approximately $220,000.

Key Headlines Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Brokerages have raised price targets and added coverage (Wells Fargo started coverage with an “overweight”; JPMorgan, Stifel and Canaccord have lifted targets near $38–$40), which supports medium‑term upside expectations.
• Neutral Sentiment: Small institutional buys have shown modest inflows from several funds in recent quarters — a limited vote of confidence but not large enough to counter recent selling.
• Negative Sentiment: CEO John C.M. Farquhar sold 22,562 shares at about $27.46 (~$619.6k), trimming his stake — insider selling by the CEO can sap near‑term sentiment and supply. Insider Selling: CEO Form 4
• Negative Sentiment: Director Julie Cullivan sold 8,000 shares at about $27.32 (~$218.6k), cutting her holding ~18% — additional insider sales amplify negative optics. Director Sale
• Negative Sentiment: Short interest surged in late January to ~4.95M shares (up ~42% vs. mid‑January), representing roughly 5.8% of float and a ~5.9 days‑to‑cover — higher short positioning can amplify downside on negative news and increases selling pressure.
• Negative Sentiment: Reports of a large shareholder sell‑off (headline coverage cited a multi‑million dollar block sale) likely added supply and weighed on the stock. Major Shareholder Sale

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.